TCI Gene Enhancing Malaysia's Preventive Healthcare In Collaboration With ALPRO Pharmacy

March 28, 2024 04:30 AM GMT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 TCI Gene Enhancing Malaysia's Preventive Healthcare In Collaboration With ALPRO Pharmacy
Image source: Kalkine Media

TAIPEI, March 28, 2024 /PRNewswire/ -- TCI Gene announced a strategic partnership with Alpro Pharmacy, a renowned chain pharmacy leader in Malaysia, to exclusively offer its genetic assessment services to Malaysians. TCI Gene and Alpro Pharmacy aims to provide Malaysians with better preventive healthcare via this initiative, complementing Alpro Pharmacy's objective of comprehensive healthcare. The service, called MyDNA360 in Malaysia, will be available to Malaysians starting the month of April 2024. It offers comprehensive genetic assessment for key critical disorders that matters to majority of Malaysians. 

Genetically inherited diseases claim the lives of 1 in 4 Malaysians. In 2020, Malaysia reported 48,639 new cancer cases, equating to 1 cancer case for every 658 Malaysians. Approximately 15% of Malaysians are diagnosed with type 2 diabetes. According to the Alzheimer's Disease Foundation Malaysia (ADFM), approximately 312% increase in Alzheimer's aging population by 2050. TCI Gene and Alpro Pharmacy believes that genetic testing can empower individuals to take proactive steps towards prevention, rather than waiting until diseases symptoms appear to seek treatment.

Alpro Pharmacy is recognized as the leading prescription pharmacy in Malaysia, celebrated for its dedication to promoting community health and conducting extensive outreach initiatives nationwide. With a comprehensive range of healthcare services, Alpro Pharmacy is strategically positioned to enhance the significance of this partnership, guaranteeing that preventive healthcare becomes increasingly accessible to all Malaysians.

TCI Gene's genetic assessment adopts globally renowned genetic detection points for high-risk diseases. This is achieved via integrating genetic medical knowledge and systems biology, analysed through big data. TCI Gene utilises their proprietary global genome databank and their artificial intelligence powered analytical engine to funnel these data, in order to get actionable results for Malaysians. TCI Gene's advanced genetic assessment prowess has been recognized by major healthcare providers in Asia. This is a significant milestone in its expansion into the Southeast Asian market.

Ms. Grace Fu, General Manager of TCI Gene, together with Ph. Low Swee Siong, Group Chief Executive Officer of Alpro Pharmacy, expressed their mutual excitement in the strategic partnership, during signing of memorandum of understanding (MOU) between the two parties.

Ph. Low Swee Siong emphasized, "This partnership symbolizes a pivotal milestone in our dedication to promoting well-being and encouraging proactive health management among individuals. By offering affordable genetic assessment services, we aim to equip Malaysians with vital information empowering them to make informed decisions concerning their health and their families' wellbeing."

"Alpro Pharmacy has always been a consistent provider of community healthcare. We are confident that TCI Gene will add value to the preventive healthcare market in Malaysia. We are looking forward to improving Malaysians' health via our predictive assessment services, in line with the country's vision of healthy population. We aim to expand the practice of the collaboration with international partners and benefit populations in the Asian region.", said Ms. Grace Fu.

To know more about your future health, please visit: www.mydna360.com

About TCI Gene (TCI):
TCI Gene has been committed to offering complete genetic testing services since 2011, while also providing personalized genetic testing auxiliary products and services, advancing towards precision personalized medicine. In 2021, it completed the development of genetic testing for cardiovascular drugs, and its pharmacogenomics testing services also applied for Laboratory Developed Tests (LDTs) in 2022. It has currently obtained national certification from TFDA as a molecular laboratory and will continue to develop pharmacogenomics testing techniques for chronic diseases such as depression and gastrointestinal disorders.

Please visit: https://www.tci-gene.com/  for more information.

About Alpro Pharmacy:
With a humble beginning starting with a single pharmacy outlet in the small town of Port Dickson in 2002, Alpro Pharmacy is now a diversified community chain pharmacy that provides comprehensive primary healthcare solutions via over 300 outlets including Alpro Pharmacy, Alpro Clinic, Alpro Physio, Alpro Baby and Alpro Audiologi, both online and offline, nationwide. It is supported by a team of more than 650 healthcare professionals, ranging from doctors, pharmacists, nutritionists, dietitians to physiotherapists and many other healthcare professionals. 

Serving more than 2 million families in Malaysia, Alpro Pharmacy is the first and only community pharmacy in the country to provide RM1 million product liability insurance to safeguard the supply of genuine medications. With over 500,000 prescriptions filled per year, Alpro Pharmacy is also the largest prescription pharmacy chain in Malaysia.

Please visit https://www.alpropharmacy.com  for more information.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next